Detection and molecular characterization of urinary tract HIV-1 populations.
Adult
Anti-Retroviral Agents
/ therapeutic use
DNA, Viral
/ genetics
Female
Genotype
HIV Infections
/ drug therapy
HIV-1
/ classification
Humans
Male
Pilot Projects
Plasma
/ virology
Prospective Studies
RNA, Viral
/ genetics
Sequence Analysis, DNA
Urinary Tract
/ virology
Viral Load
pol Gene Products, Human Immunodeficiency Virus
/ genetics
Journal
Annals of clinical microbiology and antimicrobials
ISSN: 1476-0711
Titre abrégé: Ann Clin Microbiol Antimicrob
Pays: England
ID NLM: 101152152
Informations de publication
Date de publication:
24 Sep 2019
24 Sep 2019
Historique:
received:
06
09
2018
accepted:
16
09
2019
entrez:
26
9
2019
pubmed:
26
9
2019
medline:
6
2
2020
Statut:
epublish
Résumé
Identification of all possible HIV reservoirs is an important aspect in HIV eradication efforts. The urinary tract has however not been well studied as a potential HIV reservoir. In this pilot study we molecularly characterized HIV-1 viruses in urine and plasma samples to investigate HIV-1 replication, compartmentalization and persistence in the urinary tract. Prospectively collected urine and blood samples collected over 12-36 months from 20 HIV-1 infected individuals were analysed including sampling points from prior to and after ART initiation. HIV-1 pol gene RNA and DNA from urine supernatant and urine pellets respectively were analysed and compared to plasma RNA viruses from the same individual. HIV-1 nucleic acid was detected in urine samples from at least one time point in 8/20 (40%) treatment-naïve subjects compared to 1/13 (7.7%) individuals on antiretroviral treatment (ART) during periods of plasma viral suppression and 1/7 (14.3%) individuals with virological failure. HIV-1 RNA was undetectable in urine samples after ART initiation but HIV-1 DNA was detectable in one patient more than 6 months after treatment initiation. There was co-clustering of urine-derived pol sequences but some urine-derived sequences were interspersed among the plasma-derived sequences. Suppressive ART reduces HIV-1 replication in the urinary tract but HIV-1 DNA may persist in these cells despite treatment. A larger number of sequences would be required to confirm HIV compartmentalization in the urinary tract.
Sections du résumé
BACKGROUND
BACKGROUND
Identification of all possible HIV reservoirs is an important aspect in HIV eradication efforts. The urinary tract has however not been well studied as a potential HIV reservoir. In this pilot study we molecularly characterized HIV-1 viruses in urine and plasma samples to investigate HIV-1 replication, compartmentalization and persistence in the urinary tract.
METHODS
METHODS
Prospectively collected urine and blood samples collected over 12-36 months from 20 HIV-1 infected individuals were analysed including sampling points from prior to and after ART initiation. HIV-1 pol gene RNA and DNA from urine supernatant and urine pellets respectively were analysed and compared to plasma RNA viruses from the same individual.
RESULTS
RESULTS
HIV-1 nucleic acid was detected in urine samples from at least one time point in 8/20 (40%) treatment-naïve subjects compared to 1/13 (7.7%) individuals on antiretroviral treatment (ART) during periods of plasma viral suppression and 1/7 (14.3%) individuals with virological failure. HIV-1 RNA was undetectable in urine samples after ART initiation but HIV-1 DNA was detectable in one patient more than 6 months after treatment initiation. There was co-clustering of urine-derived pol sequences but some urine-derived sequences were interspersed among the plasma-derived sequences.
CONCLUSIONS
CONCLUSIONS
Suppressive ART reduces HIV-1 replication in the urinary tract but HIV-1 DNA may persist in these cells despite treatment. A larger number of sequences would be required to confirm HIV compartmentalization in the urinary tract.
Identifiants
pubmed: 31551072
doi: 10.1186/s12941-019-0326-9
pii: 10.1186/s12941-019-0326-9
pmc: PMC6760049
doi:
Substances chimiques
Anti-Retroviral Agents
0
DNA, Viral
0
RNA, Viral
0
pol Gene Products, Human Immunodeficiency Virus
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Subventions
Organisme : National Institutes of Health, USA
ID : R01HL090312
Organisme : National Institutes of Health, USA
ID : P30AI094189
Références
N Engl J Med. 2001 Jun 28;344(26):1979-84
pubmed: 11430327
Nat Med. 2002 May;8(5):522-6
pubmed: 11984599
J Virol. 2003 May;77(9):5540-6
pubmed: 12692259
J Clin Microbiol. 1992 May;30(5):1051-5
pubmed: 1583100
J Infect Dis. 2008 Mar 1;197(5):714-20
pubmed: 18260759
AIDS Res Ther. 2009 Oct 02;6:20
pubmed: 19799780
J Am Soc Nephrol. 2011 Mar;22(3):496-507
pubmed: 21335514
Annu Rev Med. 2012;63:147-59
pubmed: 21888512
PLoS One. 2011;6(11):e28184
pubmed: 22132237
AIDS. 2012 Jul 31;26(12):1535-43
pubmed: 22441253
J Am Soc Nephrol. 2014 Feb;25(2):407-19
pubmed: 24309185
J Infect Dis. 2014 May 15;209(10):1618-22
pubmed: 24338353
AIDS. 2014 Oct 23;28(16):2345-53
pubmed: 25062092
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1126-34
pubmed: 25713386
Curr HIV/AIDS Rep. 2015 Jun;12(2):262-71
pubmed: 25914150
S Afr Med J. 2015 Mar 07;105(4):2681
pubmed: 26294888
AIDS. 2015 Aug 24;29(13):1651-7
pubmed: 26372275
Rev Med Virol. 2017 Mar;27(2):
pubmed: 28128885
PLoS One. 2017 Sep 13;12(9):e0184530
pubmed: 28902919